Launches Razumab or biosimialr of ranzibizumab, a medication given by injection into the eye, at three-fourth the price of Lucentis
by: BS Reporter 
As the first company globally, Ahmedabad-based pharma major Intas Pharmaceuticals has launched a biosimilar to Lucentis (ranibizumab), which is used to treat degenerative conditions of the eye called Razumab. It would be 25 per cent cheaper than the imported Lucentis.
A company statement here claimed that it is the first company globally to develop and launch a biosimilar version of ranibizumab, which is manufactured under strict guidelines for sterlie use in the eye. It is offered as single dose vial, thus reducing the risk of contamination during use.
Ranibizumab is a therapeutic antibody fragment designed specifically for treating degenerative conditions of the eye. It blocks the production of vascular endothelial cell growth factor A (VEGF-A), a protein which when overexpressed leads to abnormal blood vessel growth in the retina, that can cause leaks and vision loss.
Ranibizumab is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD), a common degenerative condition of the eyes in the elderly. It is also indicated for Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy in patients with Diabetic Macular Edema and vision loss resulting from choroidal neovascularization in pathologic myopia (mCNV).
“Intas’  Razumab is a 100 per cent ‘Made In India’ molecule, a feat achieved by the scientists at Intas. With the mission to provide global healthcare at affordable costs, Razumab will be about 25 per cent cheaper than the imported Lucentis in the hand of the patient. This would lead to an annual saving of about Rs. 35,000 or more in the cost of treatment to the patient, depending on the number of injections used and the clinical condition of the patient………
Read more: http://www.business-standard.com/article/companies/intas-becomes-first-global-company-to-launch-a-biosimilar-version-of-lucentis-115061900567_1.html 
Source: Business Standard

On